Huaren Pharmaceutical Co., Ltd., headquartered in China, is a prominent player in the pharmaceutical industry, specialising in the research, development, and manufacturing of high-quality medicinal products. Founded in 2001, the company has established a strong presence in both domestic and international markets, focusing on innovative solutions in areas such as oncology, cardiology, and infectious diseases. With a commitment to excellence, Huaren Pharmaceutical offers a diverse portfolio of core products, including generic medications and proprietary formulations that stand out for their efficacy and safety. The company has achieved significant milestones, including various certifications and partnerships that enhance its market position. Recognised for its dedication to quality and innovation, Huaren Pharmaceutical continues to contribute to global health advancements while maintaining a strong reputation in the competitive pharmaceutical landscape.
How does Huaren Pharmaceutical Co., Ltd.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Huaren Pharmaceutical Co., Ltd.'s score of 22 is lower than 78% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Huaren Pharmaceutical Co., Ltd., headquartered in China (CN), currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. As a result, Huaren Pharmaceutical's climate commitments remain unclear, and there is no information available regarding their strategies for addressing carbon emissions or their overall environmental impact. The lack of data may reflect a broader industry context where many pharmaceutical companies are increasingly focusing on sustainability and emissions reduction, but specific commitments from Huaren Pharmaceutical are not available at this time. Overall, without emissions data or reduction initiatives, it is challenging to assess Huaren Pharmaceutical Co., Ltd.'s position in the context of climate action and carbon management.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Huaren Pharmaceutical Co., Ltd. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
